In:
Therapeutic Advances in Urology, SAGE Publications, Vol. 10, No. 7 ( 2018-07), p. 213-221
Kurzfassung:
We investigated a thermoreversible hydrogel that is highly viscous at body temperature, while fluid-like at a low temperature, thus aiming for a slow and prolonged intravesical drug release. Our study purposed to assess antitumor efficacy of mitomycin C (MMC) mixed with hydrogel in an orthotopic rat bladder cancer model. Methods: Bladders of female Fischer F344 rats were grafted with 1.5 × 10 6 AY-27 urothelial carcinoma cells. On day 5, tumor presence was assessed by cystoscopy and rats were divided into six groups (five treatment, one control, n = 10/group). Intravesical treatments (0.5 mg or 1 mg MMC-H 2 O or MMC-hydrogel, or 2 mg MMC-hydrogel) were administered on days 5, 8 and 11. Rats were sacrificed at day 14 and bladders were evaluated. Results: Rats with tumor at cystoscopy (47/60) were evaluated for efficacy. At necropsy, all control animals (8/8) had tumors. No microscopic tumors were present in the 0.5 mg and 1 mg MMC-hydrogel groups compared with 2/8 and 1/8 rats in the 0.5 mg and 1 mg MMC-H 2 O groups ( p = 0.47 and p = 1.00, respectively). Greater toxicity was seen in animals treated with MMC-hydrogel compared with MMC-H 2 O, as demonstrated by lower body weights at necropsy ( p = 0.000) and a tendency for more severe clinical signs in the 1 and 2 mg MMC-hydrogel groups. Rats that died prematurely received 1 mg (4/10) or 2 mg (9/10) of MMC-hydrogel. Conclusions: Under the current model conditions it is unclear whether instillation of MMC-hydrogel is more effective than MMC-H 2 O. Nonetheless, the observed difference in toxicity, acting as a surrogate marker for systemic MMC exposure in the MMC-hydrogel-treated rats, supports the prolonged drug release mechanism of the hydrogel.
Materialart:
Online-Ressource
ISSN:
1756-2872
,
1756-2880
DOI:
10.1177/1756287218762064
Sprache:
Englisch
Verlag:
SAGE Publications
Publikationsdatum:
2018
ZDB Id:
2492591-3
